FREMONT, Calif., Oct. 20 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of- the-art genetic analysis research tools, today announced that Mr. Alnoor Shivji, Chairman and Chief Executive Officer, will deliver a corporate presentation at the Bio Investor Forum 2009. The conference will be held October 28 - 29, 2009, at the Palace Hotel in San Francisco.
Mr. Shivji's presentation will take place at 2:30 p.m. on Thursday October 29 in Twin Peak North conference room. The presentation will include an overview of the company's SmartChip system, which has been used successfully at the University of Pittsburg Medical Center (UPMC). As a result of the positive data, WaferGen has initiated multiple collaborations with academic research centers in the US, Europe and Japan.
About WaferGen
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping for the life science and pharmaceutical industries. The company is actively developing its SmartChip product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.
Forward-Looking Statements
This press release may contain certain "forward-looking statements". Such statements include statements relating to the recent strengthening of the leadership team of the company and other statements relating to future events or the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that : (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACTS:
Mona Chadha
Mona.chadha@wafergen.com
510.651.4450
SOURCE WaferGen Biosystems, Inc.
For further information: Mona Chadha of WaferGen Biosystems, Inc., +1-510-651-4450, Mona.chadha@wafergen.com
© PR Newswire
